

Business update – Appendix 4C for the quarter ended:

30 September 2018

MELBOURNE Australia, 30 October 2018: Imugene Limited (ASX: IMU), an immune-oncology Company is pleased to release its Appendix 4C for the quarter ended 30 September 2018.

Quarter highlights:

- **Successfully completed \$20.1 million (before costs) capital raise announced in June 2018;**
- **New cancer programs accelerate clinical development by 24 months;**
- **Established a clinical presence in the US with leaders in B-cell immunotherapeutics;**
- **HER-Vaxx Phase 1b trial recruitment completed.**

The recent quarter was one of the most significant in the growth of our company.

Imugene is now well funded to support our commercial and clinical milestones, guided by the experience of several recognised leaders in immuno-oncology.

- The successful capital raising, completed this quarter, and acquisition of new B-cell vaccine programs from the Ohio State University and The Mayo Clinic, has expanded our portfolio aimed at confirming the safety, tolerability and efficacy of several promising new immuno-oncology treatments/targets for multiple cancers including PD-1, HER1, HER2, HER3, VEGF, IGF-1R, CD28 peptides and combinations thereof.

Current Phase 1b gastric study

During the quarter our established HER-Vaxx Phase 1b/2 gastric cancer study completed recruitment. Five additional trial sites were added in recent months to accelerate the completion of the Phase 1b trial and in preparation for participating in the Phase 2 trial. Study sites have reported no safety, toxicity or tolerability issues in treated patients. All vaccinated patients have developed immune responses and antibodies to HER2.

After all patients complete their dosing protocol of the Phase 1b part of the study, the data will be analysed, a recommended Phase 2 dose chosen; we will report results to the market.

Financial position

The expansion of our activities will see an increase in expenditures.

We continue to keep a close eye on costs and manage our resources prudently.

Imugene had \$23.8 million in the bank as at 30 September 2018.

We look forward to providing further updates as we navigate several promising new therapies for multiple cancers through the clinic and into the hands of the many medical professionals and patients around the world who need them.

Leslie Chong
CEO and Managing Director
Imugene Limited
October 2018

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Imugene Limited

ABN

99 009 179 551

Quarter ended ("current quarter")

30 September 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,647)	(1,647)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(37)	(37)
(d) leased assets	-	-
(e) staff costs	(422)	(422)
(f) administration and corporate costs	(694)	(694)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	83	83
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other – <i>GST refunded</i>	21	21
1.9 Net cash from / (used in) operating activities	(2,696)	(2,696)

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	(50)	(50)
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	20	20
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(30)	(30)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares	20,114	20,114
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	(1,444)	(1,444)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	18,670	18,670

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	7,822	7,822
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,696)	(2,696)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(30)	(30)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	18,670	18,670
4.5	Effect of movement in exchange rates on cash held	69	69
4.6	Cash and cash equivalents at end of quarter	23,835	23,835

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	9,835	1,800
5.2	Call deposits	14,000	6,022
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	23,835	7,822

6. Payments to directors of the entity and their associates

6.1 Aggregate amount of payments to these parties included in item 1.2

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

163

-

Salaries, directors' fees and consulting fees at normal commercial rates.
Excludes GST where applicable.

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	
-	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
-		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(3,606)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	(408)
9.6 Administration and corporate costs	(411)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(4,425)

Note: the actual expenditure for the forecast quarter may be different depending on the opportunities, level of activity, priorities and resources available.

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:

Date: 30 October 2018

Company Secretary

Print name: Phillip Hains

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.